Get started
Author

Susie Tan

Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2019 · Aaron R. Hansen, Ian F. Tannock, et al. · The Oncologist · 46
PDF
A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.
2019 · Stephanie Lheureux, Michael Cabanero, et al. · Journal of Clinical Oncology · 21
Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.
2019 · Stephanie Lheureux, Ana Oaknin, et al. · Journal of Clinical Oncology · 14
Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.
2017 · Neesha C. Dhani, Hal W. Hirte, et al. · Journal of Clinical Oncology · 3
Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): a phase II trial in men with castration resistant prostate cancer (mCRPC).
2016 · Aaron Richard Hansen, Ian Tannock, et al. · Journal of Clinical Oncology
O7 An exploratory analysis of the impact of age, performance status, and comorbidity on clinical outcomes in a randomized phase II trial of single agent gemcitabine, vinorelbine or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly
2006 · J. Ngeow, D. Poon, et al. · Critical Reviews in Oncology/Hematology
Works count: 6
Citation count: 84
H-index: 3
I10-index: 3
Year
Topic
Type